Pharmaceutical Maker to Pay $2.2 Billion to Settle Risperdal False Marketing Cases

On the front of its Business Day section, the New York Times reports that, according to an announcement made by US Department of Justice yesterday, New Brunswick, NJ-based Johnson & Johnson “has agreed to pay more than $2.2 billion in criminal and civil fines to settle accusations that it improperly promoted the antipsychotic…Risperdal [risperidone] to older adults, children and people with developmental disabilities.”

USA Today reports that the company also has agreed to settle civil and criminal claims that it “paid kickbacks to a large pharmacy, the Justice Department said.” That pharmacy is Omnicare, “the nation’s largest pharmacy, which caters to nursing homes.”

The Wall Street Journal reports that the company will also plead guilty to a misdemeanor.

The Washington Post reports that in announcing the settlement, Attorney General Eric Holder said, “The conduct at issue in this case jeopardized the health and safety of patients and damaged the public trust. This multibillion-dollar resolution demonstrates the Justice Department’s firm commitment to preventing and combating all forms of health-care fraud. And it proves our determination to hold accountable any corporation that breaks the law and enriches its bottom line at the expense of the American people.”

Also reporting this story are the Los Angeles Times, the Chicago Tribune, and the AP.

From the American Association for Justice news release.

This entry was posted in Medical & Health Resources or Issues. Bookmark the permalink.

Comments are closed.